by The acute ischemic stroke (AIS) market is primarily driven by rising geriatric population, increasing prevalence of hypertension and diabetes, availability of advanced treatments, presence of promising pipeline candidates, and growing awareness on stroke management.
Acute ischemic stroke occurs due to blockage of blood flow to the brain caused by a blood clot. It is one of the leading causes of death and long-term disability worldwide. Currently available treatment options include tissue plasminogen activators, antiplatelet drugs, anticoagulants, thrombolytic therapy, and endovascular procedures. The increasing R&D investments by key players are focused on developing novel therapies for extended time windows and improved functional outcomes.
The Global AIS Market is estimated to be valued at US$ 10612.22 Bn in 2024 and is expected to exhibit a CAGR of 18% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the acute ischemic stroke market are F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc. They are focused on achieving faster recanalization to restore blood flow and expand treatment windows.
The growing incidence of stroke, increasing health expenditures, rising demand for effective treatments especially in developing nations are expected to drive the acute ischemic stroke market during the forecast period.
The market is witnessing increased investment from key players for expansions in emerging markets like Asia Pacific, Latin America, and Middle East & Africa. This is attributed to growing demand for advanced healthcare and rising medical tourism in these regions.
Market Key Trends
One of the key trends in the Acute Ischemic Stroke (Ais) Market is the growing preference for minimally invasive endovascular therapies over traditional open surgery. These procedures allow direct access to the clot through small incisions and help improve outcomes with lower morbidity. With ongoing technological advancements, new generation devices are providing safer recanalization at extended time windows. This is expected to revolutionize the treatment landscape and drive the acute ischemic stroke market during the forecast period.
Porter’s Analysis
Threat of new entrants: High requirement of capital and technical expertise limits threat. Bargaining power of buyers: Large patient pools and existence of alternative therapies limits buyers power. Bargaging power of suppliers: Suppliers have minimal power due presence of substitutes and intense competition. Threat of new substitutes: Threat is moderate as ongoing research may lead to new drug classes. Competitive rivalry: Intense due to existence of large and mid-size players with therapeutic alternatives.
Geographical Regions
The North American region dominated the global AIS market in terms of revenue in 2024, and is projected to lead the market during the forecast period. Factors such as rising prevalence of stroke, increasing adoption of new technologies, early availability of advanced therapy options etc. support the growth of this regional market.
The Asia Pacific region is anticipated to register the highest CAGR during the forecast period. Growing unmet needs, rising healthcare expenditure, increasing adoption of Western lifestyle, rapid growth in aging population etc. are factors attributed to growth of AIS market in emerging Asian countries.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
About Author - Money Singh
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc. LinkedIn Profile
